Abstracts tagged "DMARDs and Early Rheumatoid Arthritis"

Abstract Number: 1670 • 2015 ACR/ARHP Annual Meeting
Rapidity of Therapeutic Response of Biologics Compared to Methotrexate Monotherapy in Early RA: A Network Meta-Analysis
Raveendhara R. Bannuru, Mikala Osani, Anbuselvan Dharmarajan, Elizaveta Vaysbrot and Timothy E. McAlindon, Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Rapidity of onset of therapeutic efficacy may be critically important in the management of early RA and may reduce long-term impact of the disease.…
Abstract Number: 2382 • 2014 ACR/ARHP Annual Meeting
Adherence to Dmards in the First Six Months of Treatment in Early Arthritis Patients; Comparing Three Adherence Measures
Annelieke Pasma¹, Ethan den Boer², Adriaan van 't Spijker³, Reinier Timman³, Jan van Busschbach³ and J.M.W. Hazes⁴, ¹Rheumatology, Erasmus MC University Medical Center, Rotterdam, Netherlands, ²Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, Netherlands, ³Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose Non-adherence to DMARDs is an important indicator for the effectiveness of treatment in early arthritis patients. Reported non-adherence rates differ widely, because studies use…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].